DE1089740T1 - Behandlung von mit c. difficile toxin b verbundenen beschwerden - Google Patents
Behandlung von mit c. difficile toxin b verbundenen beschwerdenInfo
- Publication number
- DE1089740T1 DE1089740T1 DE1089740T DE99924602T DE1089740T1 DE 1089740 T1 DE1089740 T1 DE 1089740T1 DE 1089740 T DE1089740 T DE 1089740T DE 99924602 T DE99924602 T DE 99924602T DE 1089740 T1 DE1089740 T1 DE 1089740T1
- Authority
- DE
- Germany
- Prior art keywords
- toxin
- aglc
- oligosaccharide sequence
- oligosaccharide
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract 10
- 239000003053 toxin Substances 0.000 title claims 9
- 231100000765 toxin Toxicity 0.000 title claims 9
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract 38
- 101710182223 Toxin B Proteins 0.000 claims abstract 22
- 239000000203 mixture Substances 0.000 claims abstract 11
- 206010012735 Diarrhoea Diseases 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims 30
- 150000001720 carbohydrates Chemical group 0.000 claims 12
- 108700012359 toxins Proteins 0.000 claims 8
- 101000800763 Naja pallida Short neurotoxin 1 Proteins 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 3
- 101710182532 Toxin a Proteins 0.000 claims 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 abstract 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 abstract 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Ceramic Engineering (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/085,032 US6013635A (en) | 1998-05-28 | 1998-05-28 | Treatment of C. difficile toxin B associated conditions |
| PCT/CA1999/000484 WO1999061031A1 (en) | 1998-05-28 | 1999-05-27 | Treatment of c. difficile toxin b associated conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1089740T1 true DE1089740T1 (de) | 2002-06-13 |
Family
ID=22189033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1089740T Pending DE1089740T1 (de) | 1998-05-28 | 1999-05-27 | Behandlung von mit c. difficile toxin b verbundenen beschwerden |
| DE69938241T Expired - Fee Related DE69938241T2 (de) | 1998-05-28 | 1999-05-27 | Zusammensetzungen zur behandlung von durch c. difficile toxin b verursachten durchfallerkrankungen (cdad) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69938241T Expired - Fee Related DE69938241T2 (de) | 1998-05-28 | 1999-05-27 | Zusammensetzungen zur behandlung von durch c. difficile toxin b verursachten durchfallerkrankungen (cdad) |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6013635A (enExample) |
| EP (2) | EP1704865A3 (enExample) |
| JP (2) | JP2002516284A (enExample) |
| CN (1) | CN1298306A (enExample) |
| AT (1) | ATE387205T1 (enExample) |
| AU (1) | AU4125399A (enExample) |
| CA (1) | CA2321927A1 (enExample) |
| DE (2) | DE1089740T1 (enExample) |
| NO (1) | NO20005992L (enExample) |
| WO (1) | WO1999061031A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034129A (en) * | 1996-06-24 | 2000-03-07 | Geltex Pharmaceuticals, Inc. | Ionic polymers as anti-infective agents |
| US6290947B1 (en) | 1997-09-19 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin-binding agents |
| US6358930B1 (en) * | 1998-05-28 | 2002-03-19 | Synsorb Biotech Inc. | Treatment of C. difficile toxin B associated conditions |
| US6013635A (en) * | 1998-05-28 | 2000-01-11 | Synsorb Biotech, Inc. | Treatment of C. difficile toxin B associated conditions |
| US6482402B1 (en) | 1999-05-13 | 2002-11-19 | Geltex Pharmaceuticals, Inc. | Antimicrobial compositions and methods |
| US6867194B2 (en) | 2001-08-09 | 2005-03-15 | Wayne State University | Enzyme activated nitric oxide donors |
| US20050287552A1 (en) * | 2003-02-19 | 2005-12-29 | Academia Sinica, Office Of Public Affairs (Technology Transfer) | Carbohydrate encapsulated nanoparticle based affinity mass spectrometry |
| US7695738B2 (en) * | 2003-02-19 | 2010-04-13 | Academia Sinica | Carbohydrate encapsulated nanoparticles |
| EP1635771A2 (en) * | 2003-04-18 | 2006-03-22 | MERCK PATENT GmbH | Cosmetic formulations comprising antimicrobial pigments |
| GB0321996D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Nutrition Ag | Organic compounds |
| US7682631B2 (en) | 2003-10-01 | 2010-03-23 | Clemson University | Adhesin-specific nanoparticles and process for using same |
| EP1679962B1 (en) | 2003-10-20 | 2021-01-13 | Framework Therapeutics, L.L.C. | Zeolite molecular sieves for the removal of toxins |
| US20060078534A1 (en) * | 2004-10-13 | 2006-04-13 | Dominique Charmot | Toxin binding compositions |
| EP1802349A1 (en) * | 2004-10-13 | 2007-07-04 | Ilypsa, Inc. | Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| WO2008014733A1 (de) * | 2006-08-02 | 2008-02-07 | Johannes Gutenberg-Universität Mainz | Arzneimittel gegen lct-vergiftungen |
| JP5503543B2 (ja) * | 2007-09-14 | 2014-05-28 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| FR2964116B1 (fr) * | 2010-09-01 | 2017-06-02 | Biomerieux Sa | Utilisation d'un activateur de beta-glucosidase pour la detection et/ou l'identification de c.difficile |
| CN102181457B (zh) * | 2011-03-21 | 2012-07-04 | 王世霞 | 密码子优化的艰难梭菌外毒素b氨基端基因序列及其核酸疫苗 |
| GB2491117A (en) * | 2011-05-20 | 2012-11-28 | Royal Holloway & Bedford New College | Coat proteins from Clostridium and Bacillus species |
| CN104785019B (zh) * | 2015-04-09 | 2017-01-11 | 东华大学 | 异形熔喷纤维制备的高效低阻空气过滤材料 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1544908A (en) * | 1975-07-08 | 1979-04-25 | Chembiomed Ltd | Artificial oligosaccharide antigenic determinants |
| US4362720A (en) * | 1977-04-14 | 1982-12-07 | Chembiomed Ltd. | Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals |
| US5079353A (en) * | 1987-12-02 | 1992-01-07 | Chembiomed, Ltd. | Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation |
| ATE232730T1 (de) * | 1991-08-23 | 2003-03-15 | Alberta Res Council | Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten |
| US5484773A (en) * | 1994-02-14 | 1996-01-16 | Alberta Research Council | Treatment of antibiotic associated diarrhea |
| US5733579A (en) * | 1995-04-05 | 1998-03-31 | Abbott Laboratories | Oral rehydration solution containing indigestible oligosaccharides |
| US5637576A (en) * | 1995-06-05 | 1997-06-10 | Synsorb Biotech, Inc. | Treatment of traveller's diarrhea |
| US5811409A (en) * | 1995-06-05 | 1998-09-22 | Synsorb Biotech, Inc. | Treatment of cholera |
| US5846943A (en) * | 1996-11-08 | 1998-12-08 | Synsorb Biotech, Inc. | Solid support matricles containing a toxin binding oligosaccharide |
| ZA983690B (en) * | 1998-04-02 | 1999-02-04 | Synsorb Biotech Inc | Solid support matrices containing a toxin binding oligosaccharide |
| US6013635A (en) * | 1998-05-28 | 2000-01-11 | Synsorb Biotech, Inc. | Treatment of C. difficile toxin B associated conditions |
-
1998
- 1998-05-28 US US09/085,032 patent/US6013635A/en not_active Expired - Fee Related
-
1999
- 1999-05-27 JP JP2000550491A patent/JP2002516284A/ja active Pending
- 1999-05-27 CN CN99805510A patent/CN1298306A/zh active Pending
- 1999-05-27 EP EP06009088A patent/EP1704865A3/en not_active Withdrawn
- 1999-05-27 CA CA002321927A patent/CA2321927A1/en not_active Abandoned
- 1999-05-27 AU AU41253/99A patent/AU4125399A/en not_active Abandoned
- 1999-05-27 AT AT99924602T patent/ATE387205T1/de not_active IP Right Cessation
- 1999-05-27 EP EP99924602A patent/EP1089740B8/en not_active Expired - Lifetime
- 1999-05-27 WO PCT/CA1999/000484 patent/WO1999061031A1/en not_active Ceased
- 1999-05-27 DE DE1089740T patent/DE1089740T1/de active Pending
- 1999-05-27 DE DE69938241T patent/DE69938241T2/de not_active Expired - Fee Related
- 1999-10-18 US US09/419,790 patent/US6107282A/en not_active Expired - Fee Related
-
2000
- 2000-06-13 US US09/593,040 patent/US6465435B1/en not_active Expired - Fee Related
- 2000-11-27 NO NO20005992A patent/NO20005992L/no not_active Application Discontinuation
-
2006
- 2006-05-16 JP JP2006136969A patent/JP2006213735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU4125399A (en) | 1999-12-13 |
| EP1704865A2 (en) | 2006-09-27 |
| ATE387205T1 (de) | 2008-03-15 |
| EP1704865A3 (en) | 2006-12-06 |
| EP1089740A1 (en) | 2001-04-11 |
| NO20005992L (no) | 2001-01-24 |
| JP2006213735A (ja) | 2006-08-17 |
| CN1298306A (zh) | 2001-06-06 |
| WO1999061031A1 (en) | 1999-12-02 |
| CA2321927A1 (en) | 1999-12-02 |
| DE69938241T2 (de) | 2008-05-29 |
| US6465435B1 (en) | 2002-10-15 |
| US6107282A (en) | 2000-08-22 |
| JP2002516284A (ja) | 2002-06-04 |
| EP1089740B8 (en) | 2008-05-28 |
| US6013635A (en) | 2000-01-11 |
| NO20005992D0 (no) | 2000-11-27 |
| DE69938241D1 (de) | 2008-04-10 |
| EP1089740B1 (en) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1089740T1 (de) | Behandlung von mit c. difficile toxin b verbundenen beschwerden | |
| DE69616770T2 (de) | Thrombin inhibitore mit einer hirudin-ähnlichen sequenz | |
| Briggs et al. | Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo | |
| Weiser et al. | Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology, and nasopharyngeal colonization by Streptococcus pneumoniae | |
| DE69131539T2 (de) | Polypeptide mit fibrinbindungsdomäne, verwendungen und verfahren zu deren herstellung | |
| DE69433564T2 (de) | Verbindungen, die kolorektale Krebszellen spezifisch binden, und Verfahren zu ihrer Verwendung | |
| DE68922358T2 (de) | Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen. | |
| EP1005492B1 (de) | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie | |
| DE69220287T2 (de) | Bindungspeptiden | |
| DE467932T1 (de) | Plasminogen-aktivator-rezeptor vom urokinasetyp. | |
| DE1018342T1 (de) | Diagnose und Behandlung bakterieller Dysenterie | |
| Cisbani et al. | Role of the chemokine receptors CCR2 and CX3CR1 in an experimental model of thrombotic stroke | |
| DE19845798A1 (de) | Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung | |
| DE69531230T2 (de) | Metallchelate bildende Peptide und ihre Verwendung | |
| DE69331479T2 (de) | Polyethylenglycol-Hirudin-Konjugate, deren Verfahren zur Herstellung und Verwendung für die Heilung von Thrombosen | |
| DE69416078T2 (de) | Peptide mit Affinität für Entzündungen und deren radiomarkierte, diagnostische Zusammensetzungen | |
| EP0340604A2 (de) | Monoklonaler Antikörper und seine Verwendung | |
| EP0906340B2 (de) | Reinigung von faktor viii-komplex durch immunaffinitätschromatographie | |
| Das et al. | Rapid diagnosis of Campylobacter pyloridis infection | |
| CA2199180A1 (en) | Method of blocking the sec receptor | |
| DE60028248T2 (de) | Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen | |
| DE69630583T2 (de) | Peptide, bronchodilator und den blutstrom verbesserndes mittel | |
| DE69325943T3 (de) | Synthetische Polypeptide vom Hepatitis C-Virus, verwendbar für den Nachweis des Virus | |
| DE60221805T2 (de) | Peptide mit affinität zu gp120, und ihre verwendungen | |
| DE69620539T2 (de) | Verfahren zur Reinigung von Thrombomodulin |